A prospective cohort study defining utilities using time trade-offs and the euroqol-5D to assess the impact of cancer-related lymphedema

Cancer

Volumn 116, Issue 15, 2010, Pages 3722-3731

  Cheville, Andrea L ^a   Almoza, Mously ^b   Courmier, Janice N ^c   Basford, Jeffrey R ^a  

^a MAYO CLINIC   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Body mass index; Cost; Health utilities; Lymphedema; Quality of life

Indexed keywords

ADULT; AGED; ARM EDEMA; ARTICLE; BODY MASS; BREAST CANCER; CANCER STAGING; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; EUROQOL 5D; FEMALE; HUMAN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

ADULT; AGED; BODY MASS INDEX; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LYMPHEDEMA; MALE; MIDDLE AGED; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SICKNESS IMPACT PROFILE;

EID: 77955406161     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25068     Document Type: Article

References (44)

1. Moffatt CJ, Franks PJ, Doherty DC, et al. Lymphoedema: an underestimated health problem. Q J Med. 2003; 96: 731-738.
2. Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008; 1131: 147-154.
3. Fife CE, Carter MJ. Lymphedema in the morbidly obese patient: unique challenges in a unique population. Ostomy Wound Manage. 2008; 54: 44-56.
4. McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008; 26: 5213-5219.
5. Norman SA, Localio AR, Potashnik SL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009; 27: 390-397.
6. Fuller J, Guderian D, Kohler C, Schneider A, Wendt TG. Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlenther Onkol. 2008; 184: 206-211. (Pubitemid 351508127)
7. Casley-Smith JR. Alterations of untreated lymphedema and it's grades over time. Lymphology. 1995; 28: 174-185.
8. Szuba A, Rockson SG. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med. 1997; 2: 321-326.
9. Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med. 1998; 3: 145-156.
10. Medicare Benefit Policy Manual, Revision 104, 2009. Chapter 15: Covered medical and other health services. Available at: http://www.cms.gov/Manuals/ downloads/bp102c15. pdf Accessed on September 15, 2009.
11. Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009; 27: 2007-2014.
12. National Cancer Institute. Common Toxicity Criteria. Bethesda, MD: National Cancer Institute; 2003.
13. Lymphology Association of North America. Available at: http://www.clt-lana.org/ Accessed on September 15, 2009.
14. Foldi E, Foldi M. Lymphostatic diseases. In: Foldi M, Foldi E, Kubik S, eds. Textbook of Lymphology. Munich, Germany: Urban & Fischer; 2003:251.
15. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol. 2002; 12: 160-178.
16. Brent R. Measuring utilities in cost-utility analysis. In: Cost-Benefit Analysis and Health Care Evaluations. Northamptom, MA: Edward Elgar Publishing; 2004: 219-244.
17. Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics. 2007; 25: 365-384.
18. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ- 5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43: 203-220. (Pubitemid 40353904)
19. Quality AfHRa. 2005. Available at: http://www.ahrq.gov/ rice/ Accessed on June 5, 2009.
20. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985; 4: 87-90.
21. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008; 9: 171-183. (Pubitemid 351535306)
22. Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008; 108: 375-387. (Pubitemid 351431071)
23. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604-615.
24. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ("Arimidex," Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007; 106: 229-238.
25. Kilbridge KL, Weeks JC, Sober AJ, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001; 19: 812-823.
26. Pyszel A, Malyszczak K, Pyszel K, Andrzejak R, Szuba A. Disability, psychological distress and quality of life in breast cancer survivors with arm lymphedema. Lymphology. 2006; 39: 185-192. (Pubitemid 46147798)
27. Heiney SP, McWayne J, Cunningham JE, et al. Quality of life and lymphedema following breast cancer. Lymphology. 2007; 40:177-184.
28. McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer. 2005; 104: 457-466. (Pubitemid 41022801)
29. Morgan PA, Franks PJ, Moffatt CJ. Health-related quality of life with lymphoedema: a review of the literature. Int Wound J. 2005; 2: 47-62.
30. Das LK, Pani SP, Vinod SK. Locomotor disability in bancroftian filarial lymphoedema patients. J Commun Dis. 2008; 40: 13-19.
31. Harichandrakumar KT, Krishnamoorthy K, Kumari AK, Das LK. Health status of lymphatic filariasis assessed from patients using 7 domains 5 levels (7D5L) instrument. Acta Trop. 2006; 99: 137-143.
32. Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer. 2007; 110: 499-508.
33. Wilson LS, Reyes CM, Lu C, Lu M, Yen C. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma. Melanoma Res. 2002; 12: 607-617. (Pubitemid 36042748)
34. van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making. 2004; 24: 511-517.
35. Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002; 11: 447-456.
36. Bleichrodt H, Pinto JL, Abellan-Perpinan JM. A consistency test of the time trade-off. J Health Econ. 2003; 22: 1037-1052.
37. Chapman GB, Elstein AS, Kuzel TM, et al. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998; 18: 278-286.
38. O'Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making. 1995; 15: 132-137.
39. Ringash J, Redelmeier DA, O'Sullivan B, Bezjak A. Quality of life and utility in irradiated laryngeal cancer patients. Int J Radiat Oncol Biol Phys. 2000; 47: 875-881. (Pubitemid 30345583)
40. Jansen SJ, Stiggelbout AM, Wakker PP, Nooij MA, Noordijk EM, Kievit J. Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making. 2000; 20: 62-71.
41. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a 3-year follow-up study. Q J Med. 2005; 98: 343-348.
42. McNeil BW, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981; 305: 982-987. (Pubitemid 11026381)
43. Goldstein MK, Clarke AE, Michelson D, Garber AM, Bergen MR, Lenert LA. Developing and testing a multimedia presentation of a health-state description. Med Decis Making. 1994; 14: 336-344.
44. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000; 21: 587-611. (Pubitemid 30480336)